TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)


UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen

Visit link:
TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)

Related Posts